[1] 李霖,韩晨东. 戈舍瑞林联合比卡鲁胺间歇治疗对前列腺癌患者血清VEGF和miR-34a的影响[J].现代仪器与医疗,2014,23(2):45-47. [2] 周仕轶,李俊涛,张蜀武. 度他雄胺对人前列腺癌PC-3细胞移植裸鼠成瘤预防效应与机制研究[J].中国男科学杂志,2014,34(6):10-15. [3] 莫乃新,史红雷,吕忠,等. 雄激素去除治疗对老年前列腺癌和前列腺增生患者血清骨代谢的影响[J].江苏医药,2015,41(11):1280-1282. [4] 王海涛. 去势抵抗性前列腺癌精准医学研究的探索[J].中国肿瘤临床,2015,43(17):850-855. [5] 瞿旻,高旭,侯建国,等. 前列腺癌患者根治术后生化复发危险因素的单中心研究[J].中华泌尿外科杂志,2015,36(8):573-577. [6] 黄其伟,王国民,王毅. 前列腺癌相关肿瘤标志物的研究进展[J].中国临床医学,2013,34(1):99-101. [7] 李洪振,高献书,纪辰,等. 前列腺癌放疗中前列腺体积缩小与新辅助内分泌治疗时间的关系研究[J].中华放射肿瘤学杂志,2015,23(5):511-515. [8] 韩博,戚美,谭薇薇,等. 去势抵抗性前列腺癌的发生发展机制及药物治疗新进展[J].山东大学学报(医学版),2015,34(9):1-7. [9] Liu C, Armstrong C, Zhu Y,et al.Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer[J].Oncotarget,2016,34(4):90-93. [10] Manenschijn L, Hamberg P. Prolonged biochemical response after discontinuation of orteronel (TAK-700) in a patient with metastasized castration-resistant prostate cancer[J].Acta Oncol,2016,34(4):1-3. [11] Heck MM, Thaler MA, Schmid SC,et al. Chromogranin A and neuron-specific enolase serum levels as predictors of treatment outcome in metastatic castration-resistant prostate cancer patients under abiraterone therapy[J].BJU Int,2016,34(4):202-204. [12] Pilon D, Queener MK, Lefebvre P, et al. Cost per Median Overall Survival Month Associated with Abiraterone Acetate and Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer[J].J Med Econ,2016,20(5):1-28. [13] 杨金辉,代光成,许立军,等. 转移性前列腺癌化疗联合内分泌治疗1例[J].中国肿瘤临床,2015,32(9):491-493. [14] 杨恺惟,虞巍,宋毅,等. 影响多西他赛联合泼尼松治疗转移性去势抵抗性前列腺癌疗效的因素分析[J].北京大学学报(医学版),2015,32(4):592-596. [15] Chi KN, Yu EY, Jacobs C, et al. A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers[J].Ann Oncol,2016,32(4):90-93.
2016, Vol. 33 
